Touching Base

Genetic Engineering & Biotechnology News (GEN)
  • 0,0 (0)
  • МЕДИКО-БІОЛОГІЧНІ НАУКИ
  • ЩОТИЖНЯ

Touching Base is the dynamic podcast series from the editors of GEN (Genetic Engineering & Biotechnology News). Each episode features a rotating cast of senior editors including John Sterling, Kevin Davies, Julianna LeMieux, Alex Philippidis, Uduak Thomas, Corinna Singleman and Fay Lin who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next. Hosted on Acast. See acast.com/privacy for more information.

  1. 1 ДН. ТОМУ

    Women in Science, Robotics, Automation, SLAS, and Lilly Updates

    Women in Science Day (February 11) was the top of the list for discussion for GEN editors in this week’s podcast. They shared an anecdote on the history of the term “scientist”—hint it was coined for a woman. A modern scientist, Medra CEO Michelle Lee, discussed with GEN how the company is integrating robotics with AI for use in biological research. GEN attended SLAS this week and we got an update on the automation updates along with endeavors to increase the presence of women in biotech leadership. Finally, we get an update on Eli Lilly’s recent major deals followed by an update on Nektar Therapeutics clinical trial updates.     Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.    Listed below are links to the GEN stories referenced in this episode of Touching Base:    Data Is a Robotics Problem, Medra CEO Says Physical AI Will Transform Biology By Fay Lin, PhD, GEN Edge, February 11, 2026 Robots on the Red Line: A Video Update from SLAS 2026 GEN, February 11, 2026 SLAS Highlights: AI Labs, Small-Molecule SPR, Protein Interaction Assays, and Paper Labware By Uduak Thomas, GEN, February 11, 2026 SLAS Highlights: Opening Keynote Spotlights Novel Target in Genomically Unstable Tumors By Uduak Thomas, GEN, February 11, 2026 Opentrons Uses Nvidia Tech to Build Training Data That Powers Physical AI in the Lab By Uduak Thomas, GEN, February 9, 2026 Beyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System Deals By Alex Philippidis, GEN Edge, February 10, 2026 Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration By Alex Philippidis, GEN Edge, January 28, 2026 Touching Base Podcast  Hosted by Corinna Singleman, PhD    Behind the Breakthroughs  Hosted by Jonathan D. Grinstein, PhD  Hosted on Acast. See acast.com/privacy for more information.

    33 хв

  2. 30 СІЧ.

    Ex-CEO Behind Bars, 10x’s Clinical Ambitions, and Pharma’s AI Gambit

    We kick off the very first episode of 2026 with a major legal development. This week, the former CEO of CytoDyn was sentenced to 30 months in prison, more than a year after being convicted on multiple charges including four counts of securities fraud, two counts of wire fraud, and three counts of insider trading. Also, we examine recent investments in artificial intelligence by several major drugmakers, and where they are hoping the technology can make an impact. Then, the latest from 10x Genomics and its plans to expand into clinical diagnostics through new collaboration. And for some research news, a new study that explores how functional forms of amyloid can create stable memories.   Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.  Listed below are links to the GEN stories referenced in this episode of Touching Base:    Ex-CytoDyn CEO Sentenced to 30-Month Prison Term on Fraud, Insider Trading By Alex Philippidis, GEN, January 27, 2026 Pharma Bets Big on AI Platforms with Flurry of New Year Deals By Fay Lin, PhD, GEN Edge, January 22, 2026 JPM: Nvidia Launches AI Collaborations with Eli Lilly, Thermo Fisher By Alex Philippidis, GEN Edge, January 13, 2026 Clinical Ambitions: 10x Expands Beyond Research with Trio of Collaborations By Alex Philippidis, GEN Edge, January 26, 2026 Chai’s the Limit for AI Antibody Designer After $130M Series B Funding By Alex Philippidis, GEN Edge, December 16, 2025 Lilly Expands AI Ties to Insilico, from Customer to Drug Discovery Partner By Alex Philippidis, GEN Edge, November 10, 2025 How Brain May Deliberately Form Amyloids to Turn Experiences Into Memories GEN, January 26, 2026 Touching Base Podcast  Hosted by Corinna Singleman, PhD    Behind the Breakthroughs  Hosted by Jonathan D. Grinstein, PhD  Hosted on Acast. See acast.com/privacy for more information.

    34 хв

  3. 18.12.2025

    Editors’ Choice: Top Stories of 2025

    In the final episode of 2025, the GEN team came together to reflect on some of the stories over the last year that they each found impactful. Some of the stories were covered in GEN’s December issue, but our editors took the time to discuss some topics in a bit more depth during the podcast. The discussion began with an update on the progress of AI use in drug discovery. Cell and gene therapy was a big topic with the positive outcome for Baby KJ, while Sarepta dealt with a rollercoaster of a year with their DMD treatment, Elevidys. Research and biotech in Africa are growing and the discussion ranged from challenges to promise in research and development on the continent. This year’s NIH budget cuts and impacted institutions rounded out the conversation. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, Phd, Kevin Davies, Phd, John Sterling, and Uduak Thomas for a discussion of the latest biotech and biopharma news.  Listed below are links to the GEN stories referenced in this episode of Touching Base:    GEN Editors Reflect on Six of the Biggest Stories of the Year By Alex Philippidis, Savannah Wiegel, Fay Lin, PhD, Kevin Davies, PhD, Uduak Thomas, and Julianna LeMieux, PhD, GEN, December 4, 2025 StockWatch: Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment By Alex Philippidis, GEN Edge, August 10 StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks By Alex Philippidis, GEN Edge, August 3 FDA Probes Death of Brazilian Boy Linked to Sarepta’s Elevidys GEN Edge, July 27 Second DMD Patient Dies After Treatment with Sarepta Gene Therapy By Alex Philippidis, GEN Edge, June 15 DMD Patient Dies After Treatment with Sarepta Gene Therapy By Alex Philippidis, GEN Edge, March 18 From The Editor in Chief John Sterling, December Issue of GEN   Gene Therapy in Africa The State of CRISPR & Genome Editing Summit, June 11, 2025 TOP 50 NIH By Alex Philippidis, GEN, December 4, 2025 FDA Cell & Gene Therapy roundtable: Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions” By Alex Philippidis, and Kevin Davies, PhD, GEN Edge, June 5, 2025 Scientists in NYC Rally to Defend and Stand Up for Science By Corinna Singleman, GEN, March 10, 2025 Touching Base Podcast  Hosted by Corinna Singleman, PhD    Behind the Breakthroughs  Hosted by Jonathan D. Grinstein, PhD  Hosted on Acast. See acast.com/privacy for more information.

    41 хв

  4. 04.12.2025

    Lung Organoids, Autism and Sarcopenia Insights in Mice, and a Bidding War Ends

    Stories on lung organoids and autism were some of the most read this week. We kicked things off by digging into recent breakthroughs in both areas including an automated method for manufacturing iPSC-derived lung organoids and how a combination of supplements reduced autism-linked behaviors in mice. Still on the topic of new research, we discussed how a protein in the extracellular matrix helps muscle stem cells repair aging muscles. In business news, the bidding war between Lundbeck and Alkermes over Avadel Pharmaceuticals has ended. We talk about the possible implications of Lundbeck’s decision to back out and next steps for Alkermes. Then we dive into Protego Biopharma’s recent fundraising round, and efforts to develop small-molecule pharmacological chaperones that modulate protein stability in disease.     Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.    Listed below are links to the GEN stories referenced in this episode of Touching Base:    Lung Organoids Generated in Bulk Using Stirred Bioreactor Technology GEN, December 1, 2025 Autism-Linked Behaviors in Mice Reduced by Nutrient Trio GEN, December 3, 2025 Muscle Stem Cells Bolstered by ECM Protein Tenascin-C GEN, December 5, 2025   Protego Closes $130M Series B to Fund Pivotal Trial of AL Amyloidosis Candidate By Alex Philippidis, GEN Edge, December 3, 2025 Lundbeck Ends Bidding War for Avadel, After Alkermes’ Up-to-$2.37B Offer By Alex Philippidis, GEN Edge, December 1, 2025 Touching Base Podcast  Hosted by Corinna Singleman, PhD    Behind the Breakthroughs  Hosted by Jonathan D. Grinstein, PhD  Hosted on Acast. See acast.com/privacy for more information.

    36 хв

  5. 20.11.2025

    New Nasal Vaccines, Korro Stock Dips, J&J and Merck Acquisitions, and Dyno GATC

    Nasal vaccines show new promise for human papillomavirus (HPV) to address cervical cancer and whooping cough. In business news, Korro's stock craters 81% as AATD interim Phase I/II results miss expectations. Additionally, Johnson & Johnson acquires Halda to expand their cancer pipeline while Merck acquires Cidara to boost antivirals. Lastly, the inaugural Genetic Agency Technology Conference (GATC) hosted by Dyno Therapeutics brought together a diverse group of researchers, entrepreneurs, and patient advocates to discuss the mission of genetic agency, or an individual’s ability to take action at the genetic level to live a healthier life.    Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.    Listed below are links to the GEN stories referenced in this episode of Touching Base:    Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine GEN, November 15, 2025 Novel Nasal Spray Vaccine for Pertussis Shows Promise By Corinna Singleman, PhD, GEN, November 12, 2025   StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia By Alex Philippidis, GENEdge, November 16, 2025 J&J Expands Cancer Pipeline with $3B Halda Acquisition By Alex Philippidis, GENEdge, November 18, 2025 Merck to Acquire Cidara for $9.2B, Bolstering Antiviral Pipeline  By Alex Philippidis, GEN, November 15, 2025   AI Meets Genetic Agency at Dyno GATC 2025 By Fay Lin, PhD, GENEdge, November 14, 2025 Genetic Agency on Display at GATC 2025 By Kevin Davies, PhD, and Fay Lin, PhD, GEN, November 13, 2025 Dyno GATC Announces AI Agents, Muscle Capsid, and Manufacturing Partner By Fay Lin, PhD, GEN Edge, November 11, 2025   Touching Base Podcast  Hosted by Corinna Singleman, PhD    Behind the Breakthroughs  Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

    42 хв

  6. 07.11.2025

    uniQure Staggers at FDA, Recursion's Microglia Map, and Leadership Transitions

    uniQure's “game changing” data announced in September, which showed significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate AMT-130, may not be enough to secure FDA approval. We also discuss Recursion's pivotal leadership transitions, as Najat Khan, PhD, chief R&D officer and chief commercial officer, is set to take over as the company's CEO effective January 1. The AI drug developer has made big bets filling the biology data gap and recently announced a "Google Map of the brain" to advance neurodegenerative disease targets. In open-source AI for drug discovery, the release of the latest Boltz model, BoltzGen, advances the platform from structural predictions to the design of "any" therapeutic modality, all available for commercial use.    Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.      Listed below are links to the GEN stories referenced in this episode of Touching Base:     uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate  By Alex Philippidis, GEN Edge, November 3, 2025     StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data  Alex Philippidis, GEN Edge, September 28, 2025    Gene Therapy Significantly Slows Huntington Disease Progression  GEN, September 24, 2025    Recursion, Roche Unveil Microglia Map of Neuro Disease Targets  By Alex Philippidis, GEN Edge, October 29, 2025    BoltzGen Democratizes AI Therapeutic Design, Expands Druggable Universe  By Fay Lin, PhD, GEN, October 27, 2025    The State of AI in Drug Discovery On Demand      Touching Base Podcast   Hosted by Corinna Singleman, PhD     Behind the Breakthroughs   Hosted by Jonathan D. Grinstein, PhD      Hosted on Acast. See acast.com/privacy for more information.

    32 хв

  7. 24.10.2025

    Artificial Intelligence in the Emerald City and Targeting Colon Cancer Stem Cells 

    We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay Lin, PhD, visited Seattle recently for some AI-focused meetings. She discusses her experiences in the Emerald City including an exclusive in-person interview with Nobel laureate, David Baker, PhD, on what’s real and what’s hype when it comes to using AI to design proteins de novo.  Then we discuss new research from University of California, San Diego, that used machine learning to identify networks of genes that could be targeted to reprogram cancer stem cells. We also go over some early studies that point to a possible drug candidate for colon cancer.       Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.     Listed below are links to the GEN stories referenced in this episode of Touching Base:      Brunkow, Ramsdell, Sakaguchi Win Nobel Prize in Physiology or Medicine for Peripheral Immune Tolerance   Uduak Thomas, GEN, October 6, 2025      AI in Protein Design: Hype vs. Reality Explained by David Baker   By Fay Lin, PhD, GEN, October 20, 2025       Nobel Anniversary: David Baker Keynotes STEM Fundraiser by ARCS Foundation Seattle   By Fay Lin, PhD, GEN, October 14, 2025        AI Treatment Reprograms and Triggers Cancer Stem Cells to Self-Destruct   GEN, October 20, 2025        The State of AI in Drug Discovery Registration      Touching Base Podcast   Hosted by Corinna Singleman, PhD     Behind the Breakthroughs   Hosted by Jonathan D. Grinstein, PhD  Hosted on Acast. See acast.com/privacy for more information.

    24 хв

  8. 10.10.2025

    Nobel Prizes Announced and Breakthroughs for Huntington’s and Rare Diseases

    Metal-organic frameworks and peripheral immune tolerance were the big winners of the Nobel prizes in chemistry, and in physiology or medicine, respectively. In this episode of the podcast, we discuss the winners and the impacts of their discoveries. Then we move over to some business news where we discuss a novel gene therapy for Huntington’s disease from uniQure that made waves recently. Early clinical trial data for AMT-130 showed that it could meaningfully slow the progression of the disease by as much as 75%. Also in business news, a new partnership involving Arbor Biotechnologies and Chiesi Group aims to develop gene editing therapies to target rare liver diseases. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.  Listed below are links to the GEN stories referenced in this episode of Touching Base: Brunkow, Ramsdell, Sakaguchi Win Nobel Prize in Physiology or Medicine for Peripheral Immune Tolerance Uduak Thomas, GEN, October 6, 2025 Metal-Organic Frameworks Win the 2025 Nobel Prize in Chemistry Julianna LeMieux, PhD, GEN, October 8, 2025 Gene Therapy Significantly Slows Huntington Disease Progression GEN, September 24, 2025   StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data Alex Philippidis, GEN Edge, September 28, 2025   Chiesi, Arbor Target Rare Liver Diseases in Up-to-$2.1B Gene Editing Collaboration Alex Philippidis, GEN Edge, October 8, 2025 Touching Base Podcast Hosted by Corinna Singleman, PhD Hosted on Acast. See acast.com/privacy for more information.

    21 хв
Переглянути всі (43)

Опис

Touching Base is the dynamic podcast series from the editors of GEN (Genetic Engineering & Biotechnology News). Each episode features a rotating cast of senior editors including John Sterling, Kevin Davies, Julianna LeMieux, Alex Philippidis, Uduak Thomas, Corinna Singleman and Fay Lin who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next. Hosted on Acast. See acast.com/privacy for more information.

Інформація

  • Автор
    Genetic Engineering & Biotechnology News (GEN)
  • Роки діяльності
    2023 - 2026
  • Епізоди
    43
  • Категорія
    Не відверті
  • Авторське право
    © Genetic Engineering & Biotechnology News (GEN)
  • Вебсайт шоу
    Touching Base

Теж може цікавити